U.S. Markets closed

Kaleido Biosciences, Inc. (KLDO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0535-0.0095 (-15.08%)
At close: 03:56PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0630
Bid0.0000 x 1000
Ask0.0000 x 1800
Day's Range0.0510 - 0.0648
52 Week Range0.0410 - 9.4700
Avg. Volume5,362,224
Market Cap2.279M
Beta (5Y Monthly)-0.07
PE Ratio (TTM)N/A
EPS (TTM)-2.2390
Earnings DateMay 02, 2022 - May 06, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.00
  • Zacks

    Exelixis (EXEL) Initiates Early Stage Study of Lymphoma

    Exelixis (EXEL) commences the dose-escalation stage of the phase I study of XL114 in patients with non-Hodgkin's lymphoma.

  • Benzinga

    Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why

    Kaleido Biosciences Inc (NASDAQ: KLDO) has delivered formal notice to voluntarily delist its common stock from NASDAQ as the Company will stop all operations. The Company expects to file a Form 25 with the Securities and Exchange Commission by April 18 to effect the voluntary delisting effective by April 28. The Board of Directors voted to immediately wind down and cease all of the Company’s ongoing operations. Related: Kaleido Halts Upcoming Phase 2 COPD Trial, Piper Sandler Cuts Price Target.

  • Zacks

    Novartis (NVS) Beovu Gets Label Expansion for DME in EU

    Novartis (NVS) ophthalmology drug Beovus label gets expanded in EU for diabetic macular edema.